MONROVIA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in two upcoming conferences:
-
Guggenheim Healthcare Talks Forum | Oncology Day
Date: Thursday, February 13, 2020
Location: New York
Presentation Time: 9:00 a.m. EST -
9th Annual SVB Leerink Global Healthcare Conference
Date: Wednesday, February 26, 2020
Location: New York
Presentation Time: 11:00 a.m. EST
Live webcasts of these presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at . A replay of the events will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 15 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit .
View source version on businesswire.com:
